Key result
Protein kinase inhibitors are linked to PAH, driven by affinity for Src and TEC kinases.
Why the study?
The pathophysiology of pulmonary arterial hypertension induced by protein kinase inhibitors remains unclear.
Are protein kinase inhibitors associated with pulmonary arterial hypertension, and what are the underlying cellular targets?
Observational
Are protein kinase inhibitors associated with pulmonary arterial hypertension, and what are the underlying cellular targets?
Answers are grounded in this paper and cite their sources.
The study identifies an association between certain protein kinase inhibitors and pulmonary arterial hypertension, suggesting a potential pathophysiological role for Src family kinases and TEC.
The pathophysiology of pulmonary arterial hypertension (PAH) induced by protein kinase inhibitors (PKIs) remains unclear. To gain knowledge into this rare and severe pathology we performed a study combining a pharmacovigilance approach and the pharmacodynamic properties of PKIs.A disproportionality analysis on the World Health Organization pharmacovigilance database VigiBase using the reporting odds ratio (ROR) and 95% confidence interval was first performed. Then, we identified the most relevant cellular targets of interest through a systematic literature review and correlated the pharmacovigilance signals with the affinity for the different PKIs. We further performed a hierarchical cluster analysis to assess patterns of binding affinity.A positive disproportionality signal was found for dasatinib, bosutinib, ponatinib, ruxolitinib and nilotinib. Five non-receptor protein kinases significantly correlate with disproportionality signals: c-Src (r=0.79, p=0.00027), c-Yes (r=0.82, p=0.00015), Lck (r=0.81, p=0.00046) and Lyn (r=0.80, p=0.00036), all belonging to the Src protein kinase family, and TEC (r=0.85, p=0.00006). Kinases of the bone morphogenetic protein signalling pathway also seem to play a role in the pathophysiology of PKI-induced PAH. Interestingly, the dasatinib affinity profile seems to be different from that of other PKIs in the cluster analysis.The study highlights the potential role of the Src protein kinase family and TEC in PAH induced by PKIs. This approach combining pharmacovigilance and pharmacodynamics data allowed us to generate some hypotheses about the pathophysiology of the disease; however, the results have to be confirmed by further studies.
No takes yet. Share an insight, caveat, or question.
Cornet et al. (2019) conducted an observational in Pulmonary arterial hypertension associated with protein kinase inhibitors. Protein kinase inhibitors was evaluated on Disproportionality signal (reporting odds ratio) for PAH and correlation with kinase affinity. Protein kinase inhibitors showed positive disproportionality signals for PAH, which correlated with affinity for Src family kinases and TEC.
Synapse has enriched 10 related papers. Consider them for comparative context: